In the bustling world of health tech startups, one name is quickly rising to the forefront: Olutosin Alabi. The Nigerian-born entrepreneur and current MBA candidate at Syracuse University's Whitman School of Management is making waves with her innovative approach to managing one of diabetes' most pervasive complications: foot ulcers.
Alabi's company, DiabeTech, is poised to disrupt the $50 billion global diabetes care market with its AI-powered wearable technology. "We're not just creating a product," Alabi explains, "we're igniting a movement towards patient empowerment in diabetes management."
DiabeTech's platform integrates electronic tattoo sensors, AI analytics, and a user-friendly mobile app to provide real-time monitoring and personalized treatment recommendations for diabetic foot ulcer patients. This novel approach could significantly reduce the $9.1 billion spent annually on diabetic foot ulcer treatment in the U.S. alone. Alabi said, "I see immense potential in this innovation. DiabeTech addresses a critical gap in diabetes care. By providing continuous monitoring and early intervention, we could potentially prevent thousands of amputations each year."
Alabi's journey from software engineer to health tech innovator is as impressive as her product. With a BSc in Computing from the University of Greenwich and an MSc in Information Technology from The Open University, Alabi brings a unique blend of technical expertise and business acumen to the healthcare sector. Her entrepreneurial prowess hasn't gone unnoticed. Alabi's track record of success dates back to 2012 when she received the Youth Enterprise with Innovation in Nigeria award, in conjunction with the World Bank. This early recognition set the stage for a series of accolades, including the Bank of Industry Nigeria YES Grant in 2016 and the Tony Elumelu Foundation Business Award in 2018.Most recently, in 2024, Alabi has been on a winning streak. She secured business grants in the Afroprenure Competition, followed by a win in the Raymond von Dran iPrize Competition. The crowning achievement came with victory in the Whitman School of Management Dean's Innovation Competition, among others.
Sarah Johnson, a partner at eHealthTech Ventures, sees Alabi as a rising star in the industry. "Olutosin represents the best of what young entrepreneurs can achieve when they combine technical expertise with a deep understanding of real-world problems," Johnson states. "Her consistent recognition across various competitions speaks volumes about her potential to disrupt the healthcare industry."
With the global digital health market projected to reach $639.4 billion by 2026, according to MarketsandMarkets research, Alabi's timing couldn't be better. Olutosin Alabi is not just positioned to transform diabetic care – she's on track to become a formidable player in the health tech industry, backed by a strong history of entrepreneurial success and recognition.
Media Contact
Company Name: DiabeTech
Contact Person: Olutosin Alabi
Email: Send Email
Country: United States
Website: diabetech.io
